REG - Beximco Pharmaceut - Statement re: media comment

Beximco PharmaceuticalsAnnouncement

24/11/2021 07:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211124:nRSX4286Ta&default-theme=true

RNS Number : 4286T  Beximco Pharmaceuticals Ltd  24 November 2021

24 November 2021

 

BEXIMCO PHARMACEUTICALS LTD.

 

Statement re: media comment

 

Beximco Pharmaceuticals Limited ("Beximco Pharma" or "the Company"; AIM
Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical ingredients, notes
recent media reports in Bangladesh relating to Covid-19 vaccine supplies.

 

Reports suggest that the Serum Institute of India Private Limited (SII) will
resume exports of Covid-19 vaccine doses into Bangladesh in December 2021.
However, in line with the Company's announcement on 11 October 2021, Beximco
Pharma is yet to receive any confirmation from SII in this regard. The Company
remains in dialogue with the Government of Bangladesh and SII and a further
announcement will be made as appropriate.

 

Reports also suggest that Beximco Pharma is building its own capacity to
produce Covid-19 vaccines and that this capability could be operational within
four-to-six weeks. While the Company can confirm that, as part of its ongoing
mission to provide patients with affordable treatment options, it is in the
process of establishing an in-house vaccine capability, this is still at an
early stage. No decision has been made on whether this vaccine capability will
focus on Covid-19 or other target disease areas. As above, any material
developments will be announced as appropriate.

 

For further information please visit www.beximcopharma.com
(http://www.beximcopharma.com) or enquire to:

 

 Beximco Pharma
 Nazmul Hassan MP, Managing Director

 Tel: +880 2 58611001, ext.20080

 S M Rabbur Reza, Chief Operating Officer

 Tel: +880 2 58611001, ext. 20111

 Mohammad Ali Nawaz, Chief Financial Officer

 Tel: +880 2 58611001, ext.20030

 SPARK Advisory Partners Limited (Nominated Adviser)

 Mark Brady / Andrew Emmott

 Tel: +44 (0)20 3368 3551 / 3555

 SP Angel Corporate Finance LLP (Broker)

 Vadim Alexandre / Abigail Wayne

 Tel: +44 (0) 20 3470 0470

 FTI Consulting

 Simon Conway / Victoria Foster Mitchell / Sam Purewal

 Tel: +44 (0)20 3727 1000

 

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 5,500 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the world.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SPCDZLBLFFLZFBF